Single ketamine infusion and neurocognitive performance in bipolar depression

Pharmacopsychiatry. 2015 Mar;48(2):78-9. doi: 10.1055/s-0034-1394399. Epub 2014 Oct 27.

Abstract

We estimated neurocognitive performance using the trail making test (TMT) and the Stroop color-word interference test before, and on the 3(rd) day after a single infusion of ketamine, in 18 bipolar depressed patients receiving mood-stabilizing drugs. The performance on all tests significantly improved on the 3(rd) day after ketamine infusion which correlated positively with baseline intensity of neuropsychological impairment and was not associated either with baseline intensity of depression or reduction of depressive symptoms after 3 or 7 days. The results suggest that in such population of patients, single ketamine infusion may improve neuropsychological performance independently of antidepressant effect.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Bipolar Disorder / psychology*
  • Depression / psychology
  • Female
  • Humans
  • Infusions, Intravenous
  • Ketamine / administration & dosage*
  • Ketamine / pharmacology*
  • Male
  • Middle Aged
  • Psychomotor Performance / drug effects*

Substances

  • Ketamine